How much profit has ImmunoGen made this year?
ImmunoGen has made 107.05 M USD this year.
ImmunoGen Net Income 2024
ImmunoGen Net Income
107.05 M USD
Ticker
IMGN
ISIN
US45253H1014
WKN
878613
In 2024, ImmunoGen's profit amounted to 107.05 M USD, a 396.25% increase from the 21.57 M USD profit recorded in the previous year.
The ImmunoGen Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2029e | 549.93 |
| 2028e | 595.52 |
| 2027e | 530.92 |
| 2026e | 403.39 |
| 2025e | 244.57 |
| 2024e | 107.05 |
| 2023e | 21.57 |
| 2022 | -222.9 |
| 2021 | -139.3 |
| 2020 | -44.4 |
| 2019 | -104.1 |
| 2018 | -168.8 |
| 2017 | -96 |
| 2016 | -144.8 |
| 2015 | -60.7 |
| 2014 | -71.4 |
| 2013 | -72.8 |
| 2012 | -73.3 |
| 2011 | -58.3 |
| 2010 | -50.9 |
| 2009 | -31.9 |
| 2008 | -32 |
| 2007 | -19 |
| 2006 | -17.8 |
| 2005 | -11 |
| 2004 | -5.9 |
| 2003 | -20 |
ImmunoGen Revenue, EBIT, Net Income US45253H1014 · 878613
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into ImmunoGen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ImmunoGen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ImmunoGen’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of ImmunoGen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into ImmunoGen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing ImmunoGen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ImmunoGen’s growth potential.
ImmunoGen Revenue, Profit, and EBIT History
| Date | ImmunoGen Revenue | ImmunoGen EBIT | ImmunoGen Net Income |
|---|---|---|---|
| 2029e | 1.3 B undefined | 0 undefined | 549.93 M undefined |
| 2028e | 1.32 B undefined | 734.1 M undefined | 595.52 M undefined |
| 2027e | 1.22 B undefined | 615.47 M undefined | 530.92 M undefined |
| 2026e | 1.03 B undefined | 466.61 M undefined | 403.39 M undefined |
| 2025e | 794.2 M undefined | 277.81 M undefined | 244.57 M undefined |
| 2024e | 560.86 M undefined | 116.72 M undefined | 107.05 M undefined |
| 2023e | 384.16 M undefined | 15.27 M undefined | 21.57 M undefined |
| 2022 | 108.8 M undefined | -220.9 M undefined | -222.9 M undefined |
| 2021 | 69.9 M undefined | -125.1 M undefined | -139.3 M undefined |
| 2020 | 132.3 M undefined | -20.9 M undefined | -44.4 M undefined |
| 2019 | 82.3 M undefined | -70.8 M undefined | -104.1 M undefined |
| 2018 | 53.4 M undefined | -157.7 M undefined | -168.8 M undefined |
| 2017 | 115.4 M undefined | -58.2 M undefined | -96 M undefined |
| 2016 | 60 M undefined | -125 M undefined | -144.8 M undefined |
| 2015 | 85.5 M undefined | -54.5 M undefined | -60.7 M undefined |
| 2014 | 59.9 M undefined | -71.5 M undefined | -71.4 M undefined |
| 2013 | 35.5 M undefined | -73 M undefined | -72.8 M undefined |
| 2012 | 16.4 M undefined | -73.3 M undefined | -73.3 M undefined |
| 2011 | 19.3 M undefined | -60.2 M undefined | -58.3 M undefined |
| 2010 | 13.9 M undefined | -51.2 M undefined | -50.9 M undefined |
| 2009 | 28 M undefined | -31.8 M undefined | -31.9 M undefined |
| 2008 | 40.2 M undefined | -34.1 M undefined | -32 M undefined |
| 2007 | 38.2 M undefined | -22.2 M undefined | -19 M undefined |
| 2006 | 32.1 M undefined | -21.4 M undefined | -17.8 M undefined |
| 2005 | 35.7 M undefined | -12.7 M undefined | -11 M undefined |
| 2004 | 26 M undefined | -8.4 M undefined | -5.9 M undefined |
| 2003 | 7.6 M undefined | -24.6 M undefined | -20 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2003 | 7.6 M USD | -24.6 M USD | -20 M USD |
| 2004 | 26 M USD | -8.4 M USD | -5.9 M USD |
| 2005 | 35.7 M USD | -12.7 M USD | -11 M USD |
| 2006 | 32.1 M USD | -21.4 M USD | -17.8 M USD |
| 2007 | 38.2 M USD | -22.2 M USD | -19 M USD |
| 2008 | 40.2 M USD | -34.1 M USD | -32 M USD |
| 2009 | 28 M USD | -31.8 M USD | -31.9 M USD |
| 2010 | 13.9 M USD | -51.2 M USD | -50.9 M USD |
| 2011 | 19.3 M USD | -60.2 M USD | -58.3 M USD |
| 2012 | 16.4 M USD | -73.3 M USD | -73.3 M USD |
| 2013 | 35.5 M USD | -73 M USD | -72.8 M USD |
| 2014 | 59.9 M USD | -71.5 M USD | -71.4 M USD |
| 2015 | 85.5 M USD | -54.5 M USD | -60.7 M USD |
| 2016 | 60 M USD | -125 M USD | -144.8 M USD |
| 2017 | 115.4 M USD | -58.2 M USD | -96 M USD |
| 2018 | 53.4 M USD | -157.7 M USD | -168.8 M USD |
| 2019 | 82.3 M USD | -70.8 M USD | -104.1 M USD |
| 2020 | 132.3 M USD | -20.9 M USD | -44.4 M USD |
| 2021 | 69.9 M USD | -125.1 M USD | -139.3 M USD |
| 2022 | 108.8 M USD | -220.9 M USD | -222.9 M USD |
| 2023e | 384.16 M USD | 15.27 M USD | 21.57 M USD |
| 2024e | 560.86 M USD | 116.72 M USD | 107.05 M USD |
| 2025e | 794.2 M USD | 277.81 M USD | 244.57 M USD |
| 2026e | 1.03 B USD | 466.61 M USD | 403.39 M USD |
| 2027e | 1.22 B USD | 615.47 M USD | 530.92 M USD |
| 2028e | 1.32 B USD | 734.1 M USD | 595.52 M USD |
| 2029e | 1.3 B USD | 0 USD | 549.93 M USD |
ImmunoGen stock margins US45253H1014 · 878613
The ImmunoGen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ImmunoGen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ImmunoGen.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the ImmunoGen's sales revenue. A higher gross margin percentage indicates that the ImmunoGen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the ImmunoGen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the ImmunoGen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ImmunoGen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ImmunoGen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ImmunoGen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
ImmunoGen Margin History
| ImmunoGen Gross margin | ImmunoGen Profit margin | ImmunoGen EBIT margin | ImmunoGen Profit margin |
|---|---|---|---|
| 2029e | 99.82 % | 0 % | 42.24 % |
| 2028e | 99.82 % | 55.57 % | 45.08 % |
| 2027e | 99.82 % | 50.45 % | 43.52 % |
| 2026e | 99.82 % | 45.39 % | 39.24 % |
| 2025e | 99.82 % | 34.98 % | 30.79 % |
| 2024e | 99.82 % | 20.81 % | 19.09 % |
| 2023e | 99.82 % | 3.98 % | 5.62 % |
| 2022 | 99.82 % | -203.03 % | -204.87 % |
| 2021 | 99.82 % | -178.97 % | -199.28 % |
| 2020 | 99.82 % | -15.8 % | -33.56 % |
| 2019 | 99.82 % | -86.03 % | -126.49 % |
| 2018 | 99.82 % | -295.32 % | -316.1 % |
| 2017 | 99.82 % | -50.43 % | -83.19 % |
| 2016 | 99.82 % | -208.33 % | -241.33 % |
| 2015 | 99.82 % | -63.74 % | -70.99 % |
| 2014 | 99.82 % | -119.37 % | -119.2 % |
| 2013 | 99.82 % | -205.63 % | -205.07 % |
| 2012 | 99.82 % | -446.95 % | -446.95 % |
| 2011 | 99.82 % | -311.92 % | -302.07 % |
| 2010 | 99.82 % | -368.35 % | -366.19 % |
| 2009 | 99.82 % | -113.57 % | -113.93 % |
| 2008 | 99.82 % | -84.83 % | -79.6 % |
| 2007 | 99.82 % | -58.12 % | -49.74 % |
| 2006 | 91.59 % | -66.67 % | -55.45 % |
| 2005 | 74.23 % | -35.57 % | -30.81 % |
| 2004 | 78.08 % | -32.31 % | -22.69 % |
| 2003 | 63.16 % | -323.68 % | -263.16 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2003 | 63.16 % | -323.68 % | -263.16 % |
| 2004 | 78.08 % | -32.31 % | -22.69 % |
| 2005 | 74.23 % | -35.57 % | -30.81 % |
| 2006 | 91.59 % | -66.67 % | -55.45 % |
| 2007 | 99.82 % | -58.12 % | -49.74 % |
| 2008 | 99.82 % | -84.83 % | -79.6 % |
| 2009 | 99.82 % | -113.57 % | -113.93 % |
| 2010 | 99.82 % | -368.35 % | -366.19 % |
| 2011 | 99.82 % | -311.92 % | -302.07 % |
| 2012 | 99.82 % | -446.95 % | -446.95 % |
| 2013 | 99.82 % | -205.63 % | -205.07 % |
| 2014 | 99.82 % | -119.37 % | -119.2 % |
| 2015 | 99.82 % | -63.74 % | -70.99 % |
| 2016 | 99.82 % | -208.33 % | -241.33 % |
| 2017 | 99.82 % | -50.43 % | -83.19 % |
| 2018 | 99.82 % | -295.32 % | -316.1 % |
| 2019 | 99.82 % | -86.03 % | -126.49 % |
| 2020 | 99.82 % | -15.8 % | -33.56 % |
| 2021 | 99.82 % | -178.97 % | -199.28 % |
| 2022 | 99.82 % | -203.03 % | -204.87 % |
| 2023e | 99.82 % | 3.98 % | 5.62 % |
| 2024e | 99.82 % | 20.81 % | 19.09 % |
| 2025e | 99.82 % | 34.98 % | 30.79 % |
| 2026e | 99.82 % | 45.39 % | 39.24 % |
| 2027e | 99.82 % | 50.45 % | 43.52 % |
| 2028e | 99.82 % | 55.57 % | 45.08 % |
| 2029e | 99.82 % | 0 % | 42.24 % |
ImmunoGen Aktienanalyse
What does ImmunoGen do?
ImmunoGen Inc is a leading company in the biotechnology industry. The company was founded in 1981 as a research facility. In recent decades, ImmunoGen Inc has specialized in the development of antibody-drug conjugates (ADCs). ADCs are drugs that consist of an antibody and a cytotoxin that specifically targets tumor cells. In this way, cancer cells can be selectively destroyed without damaging surrounding tissue. ImmunoGen Inc has achieved success in recent years, particularly in the development of ADCs against serious cancers such as lung cancer or breast cancer, and it also collaborates with major pharmaceutical companies such as Roche or Bayer. The business model of ImmunoGen Inc, therefore, consists of developing innovative cancer drugs and successfully bringing them to market. Another branch of the company is the development of therapeutics for other diseases such as rheumatoid arthritis or multiple sclerosis. ImmunoGen Inc also utilizes ADCs to selectively destroy disease-specific cells in these cases. In the past, ImmunoGen Inc has successfully launched several products on the market. For example, in 2019, the cancer drug Kadcyla, manufactured by Roche and based on ImmunoGen's ADC technology, was approved by the US Food and Drug Administration (FDA) for the treatment of certain types of breast cancer. The ADC development candidate IMGN632 also shows promising results in the treatment of acute myeloid leukemia and other cancer diseases. The history of ImmunoGen Inc has also been marked by some challenges. In the early years of the company, it faced financial difficulties and sold a large number of shares to an investor in 1999. However, the company remained diligent in research and development and eventually became one of the leading biotech companies in the field of cancer research with the development of ADCs. Nevertheless, the company has also experienced setbacks in the development of products and has had to discontinue several development programs. Despite everything, ImmunoGen Inc is considered a successful company in the biotechnology industry, effectively marketing its innovative solutions in the oncology market. It is also being closely watched to see whether future ADCs will not have to undergo as long development cycles as their predecessors, which can guarantee long-term success for the company. ImmunoGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding ImmunoGen's Profit Margins
The profit margins of ImmunoGen represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of ImmunoGen's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating ImmunoGen's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
ImmunoGen's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When ImmunoGen’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about ImmunoGen Stock
How has the profit developed compared to last year?
The profit has increased by 396.25% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does ImmunoGen publish its earnings?
ImmunoGen publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of ImmunoGen?
The profits of ImmunoGen are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of ImmunoGen?
You can learn more about the earnings of ImmunoGen by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does ImmunoGen pay?
Over the past 12 months, ImmunoGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmunoGen is expected to pay a dividend of 0 USD.
What is the dividend yield of ImmunoGen?
The current dividend yield of ImmunoGen is .
When does ImmunoGen pay dividends?
ImmunoGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmunoGen?
ImmunoGen paid dividends every year for the past 0 years.
What is the dividend of ImmunoGen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmunoGen located?
ImmunoGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmunoGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmunoGen from 6/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/26/2024.
When did ImmunoGen pay the last dividend?
The last dividend was paid out on 6/26/2024.
What was the dividend of ImmunoGen in the year 2023?
In the year 2023, ImmunoGen distributed 0 USD as dividends.
In which currency does ImmunoGen pay out the dividend?
The dividends of ImmunoGen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImmunoGen
Our stock analysis for ImmunoGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmunoGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
